Trial Profile
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Cobolimab (Primary) ; Docetaxel; Dostarlimab; Encelimab; Nivolumab
- Indications Colorectal cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Peritoneal cancer; Skin cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms AMBER
- Sponsors GlaxoSmithKline; GSK; TESARO
- 09 Dec 2022 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 369 to 475, treatment arm changed from 15 to 16
- 09 Dec 2022 Planned number of patients changed from 369 to 475.
- 09 Dec 2022 Planned End Date changed from 3 Oct 2024 to 15 Jul 2025.